Mimedx Group
Open
$3.34
Prev. Close
$3.34
High
$3.37
Low
$3.34
Market Snapshot
$456.9M
9.4
0.28
$348.88M
808
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 808 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
emptyResult
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 808 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Recently from Cashu
MiMedx Group Reports Strong Q4 Growth and Ambitious Future Projections in Regenerative Medicine
MiMedx Group: A Strong Surge in Regenerative Medicine MiMedx Group showcases impressive performance in its Q4 earnings report, which reflects a significant upward trajectory driven by robust demand fo…
MiMedx Group Sees 15% Revenue Growth in Q4, Driven by Regenerative Medicine Demand
MiMedx Group Posts Robust Financial Results, Driven by Regenerative Medicine Growth MiMedx Group delivers strong Q4 performance, showcasing a significant year-over-year revenue increase of 15% to $100…
MiMedx Group Reports Strong Q4 Earnings Driven by Regenerative Medicine Growth and Future Outlook
MiMedx Group Reports Strong Q4 Earnings, Highlighting Regenerative Medicine Growth MiMedx Group (NASDAQ: MDXG) reveals a robust financial performance for its fourth quarter of 2026, demonstrating sign…
Mimedx Group Experiences Strong Demand Surge and Financial Growth in Regenerative Medicine
Mimedx Group Sees Surge in Demand for Flagship Products Amid Strong Financial Results Mimedx Group reports a significant uptick in demand for its flagship regenerative medicine products, indicating a…